Literature DB >> 12829822

Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids.

Julie Bestman-Smith1, Guy Boivin.   

Abstract

Herpes simplex virus (HSV) DNA polymerase (Pol) mutations can confer resistance to all currently available antiherpetic drugs. However, discrimination between mutations responsible for drug resistance and those that are part of viral polymorphism can be difficult with current methodologies. A new system is reported for rapid generation of recombinant HSV type 1 (HSV-1) DNA Pol mutants based on transfection of a set of overlapping viral cosmids and plasmids. With this approach, twenty HSV-1 recombinants with single or dual mutations within the DNA pol gene were successfully generated and subsequently evaluated for their susceptibilities to acyclovir (ACV), foscarnet (FOS), cidofovir (CDV), and adefovir (ADV). Mutations within DNA Pol conserved regions II (A719T and S724N), VI (L778M, D780N, and L782I), and I (F891C) were shown to induce cross-resistance to ACV, FOS, and ADV, with two of these mutations (S724N and L778M) also conferring significant reduction in CDV susceptibility. Mutant F891C was associated with the highest levels of resistance towards ACV and FOS and was strongly impaired in its replication capacity. One mutation (D907V) lying outside of the conserved regions was also associated with this ACV-, FOS-, and ADV-resistant phenotype. Some mutations (K522E and Y577H) within the delta-region C were lethal, whereas others (P561S and V573M) induced no resistance to any of the drugs tested. Recombinants harboring mutations within conserved regions V (N961K) and VII (Y941H) were resistant to ACV but susceptible to FOS. Finally, mutations within conserved region III were associated with various susceptibility profiles. This new system allows a rapid and accurate evaluation of the functional role of various DNA Pol mutations, which should translate into improved management of drug-resistant HSV infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829822      PMCID: PMC161916          DOI: 10.1128/jvi.77.14.7820-7829.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Structure of the replicating complex of a pol alpha family DNA polymerase.

Authors:  M C Franklin; J Wang; T A Steitz
Journal:  Cell       Date:  2001-06-01       Impact factor: 41.582

2.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed.

Authors:  I Schmit; G Boivin
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes.

Authors:  T Eckle; L Prix; G Jahn; T Klingebiel; R Handgretinger; B Selle; K Hamprecht
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

5.  Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene.

Authors:  G Andrei; R Snoeck; E De Clercq; R Esnouf; P Fiten; G Opdenakker
Journal:  J Gen Virol       Date:  2000-03       Impact factor: 3.891

6.  Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.

Authors:  Julie Bestman-Smith; Guy Boivin
Journal:  J Med Virol       Date:  2002-05       Impact factor: 2.327

7.  Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.

Authors:  D A Jabs; B K Martin; M S Forman; J P Dunn; J L Davis; D V Weinberg; K K Biron; F Baldanti
Journal:  J Infect Dis       Date:  2000-12-15       Impact factor: 5.226

Review 8.  Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms.

Authors:  Christian Gilbert; Julie Bestman-Smith; Guy Boivin
Journal:  Drug Resist Updat       Date:  2002-04       Impact factor: 18.500

9.  Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.

Authors:  Masayuki Saijo; Yukiharu Yasuda; Hiromasa Yabe; Shunichi Kato; Tatsuo Suzutani; Erik De Clercq; Masahiro Niikura; Akihiko Maeda; Ichiro Kurane; Shigeru Morikawa
Journal:  J Med Virol       Date:  2002-09       Impact factor: 2.327

10.  Assessing the contribution of the herpes simplex virus DNA polymerase to spontaneous mutations.

Authors:  Karen E Duffy; Matthew R Quail; Tammy T Nguyen; Robert J Wittrock; Joan O Bartus; Wendy M Halsey; Jeffry J Leary; Teresa H Bacon; Robert T Sarisky
Journal:  BMC Infect Dis       Date:  2002-05-07       Impact factor: 3.090

View more
  25 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  A genetic system for rhesus monkey rhadinovirus: use of recombinant virus to quantitate antibody-mediated neutralization.

Authors:  John P Bilello; Jennifer S Morgan; Blossom Damania; Sabine M Lang; Ronald C Desrosiers
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir.

Authors:  Joel B Epstein; Sara Gharapetian; Ali R Rejali; Rachel Zabner; Michael Lill; Dimitrios Tzachanis
Journal:  Support Care Cancer       Date:  2016-05-10       Impact factor: 3.603

6.  New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

7.  Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Robert A Smith; Donovan J Anderson; Bradley D Preston
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

8.  Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Authors:  Natacha Coen; Sophie Duraffour; Dimitri Topalis; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

9.  Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Authors:  Sonia Burrel; Claire Deback; Henri Agut; David Boutolleau
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

10.  Selection and characterization of Autographa californica multiple nucleopolyhedrovirus DNA polymerase mutations.

Authors:  Guozhong Feng; David K Thumbi; Jondavid de Jong; Jeffrey J Hodgson; Basil M Arif; Daniel Doucet; Peter J Krell
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.